Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

76.59
-0.0100-0.01%
Post-market: 76.590.00000.00%16:54 EDT
Volume:2.06M
Turnover:157.22M
Market Cap:15.00B
PE:-21.46
High:77.24
Open:76.20
Low:75.02
Close:76.60
52wk High:93.42
52wk Low:48.78
Shares:195.81M
Float Shares:167.00M
Volume Ratio:1.42
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.96
PE(LYR):-20.24

Loading ...

Bridgebio Pharma - FDA not Planning Advisory Committee Meeting for Encaleret Nda

THOMSON REUTERS
·
Jul 22

Bridgebio Announces FDA Acceptance of Nda for Encaleret for Adh1

THOMSON REUTERS
·
Jul 22

Bridgebio Pharma - Phase 3 Calibrate Trial of Encaleret in Adh1 Achieves All Primary and Key Secondary Endpoints

THOMSON REUTERS
·
Jul 22

Bridgebio Pharma - FDA Sets Pdufa Target Action Date of May 8, 2027 for Encaleret Nda

THOMSON REUTERS
·
Jul 22

U.S. Research Roundup- Anterix, Fidus Investment, Nextpower

Reuters
·
Jul 20

Bridgebio Pharma Inc : Jefferies Raises Target Price to $110 from $100

THOMSON REUTERS
·
Jul 20

Yext, Mission Produce, and 3 More Stocks See Action from Activist Investors

Dow Jones
·
Jul 18

Bridgebio Pharma is Maintained at Neutral by Citigroup

Dow Jones
·
Jul 17

Bridgebio Pharma Inc : Citigroup Raises Target Price to $93 from $82

THOMSON REUTERS
·
Jul 16

Bridgebio Pharma Director Jennifer E. Cook Reports Disposal of Common Shares Worth $13.1 Million

Reuters
·
Jul 14

Bridgebio Pharma is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 13

Bridgebio Grants 83,283 Restricted Stock Units to 37 New Employees Under Inducement Plan

Reuters
·
Jul 11

Bridgebio Pharma Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 11

Movement Alert|BridgeBio Pharma Falls 5.02% in Regular Trading, Broad Biotech Sector Selloff Triggers Profit-Taking After Recent Rally

Market Focus
·
Jul 11

Alnylam, Bridgebio Gain from Astrazeneca-ionis Drug Missing Target

Dow Jones
·
Jul 10

AstraZeneca PLC Stock (AZN) Moved Down by 6.72% on Jul 9: A Full Analysis

TradingKey
·
Jul 09

Bridgebio Pharma up over 14%, on Track for Record High Close

Dow Jones
·
Jul 09

Movement Alert|BridgeBio Pharma Rises 10.17% in Regular Trading, $1 Billion Preferred Equity Financing from KKR and Sixth Street to Accelerate Rare Disease Drug Commercialization

Market Focus
·
Jul 09

BridgeBio Pharma (BBIO) Receives a Buy from Piper Sandler

TIPRANKS
·
Jul 09

S&P 500 Futures Climb in Premarket Trading; Alnylam Pharmaceuticals, Bridgebio Pharma Lead

Dow Jones
·
Jul 09